Link to this page
Biological and Environmental Research Ontology
| Id | http://purl.obolibrary.org/obo/NCIT_C79828
http://purl.obolibrary.org/obo/NCIT_C79828
|
|---|---|
| Preferred Name | Cixutumumab |
| Definitions |
A fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis. |
|---|---|
| prefLabel | Cixutumumab
|
| label | Cixutumumab
|
| PDQ_Closed_Trial_Search_ID | 561575
|
| code | C79828
|
| Has_Target | |
| prefixIRI | NCIT:C79828
|
| in_subset |
See more
See less
|
| Display_Name | Cixutumumab
|
| Preferred_Name | Cixutumumab
|
| FDA_UNII_Code | 2285XW22DR
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Cixutumumab
|
| CAS_Registry | 947687-12-9
|
| NCI_Drug_Dictionary_ID | 561575
|
| Legacy Concept Name | Cixutumumab
|
| type | |
| ALT_DEFINITION | A substance being studied in the treatment of some types of cancer. It is a monoclonal antibody that is made in the laboratory and can bind to substances in the body. Cixutumumab blocks the action of a protein needed for cell growth and may kill cancer cells. It is a type of insulin-like growth factor-1 receptor (IGF-1R) inhibitor.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 561575
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
Immunologic Factor
|
| UMLS_CUI | C2703174
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |